Physician
Hematology
Dr. Yasuhiro Oki, MD
|
|
Give Review
Yasuhiro is an expert in the field of Hematology. He graduated from Graduate School of Medicine and Faculty of Medicine, The University of Tokyo. Doctor Yasuhiro Oki, MD is a published physician. He has 78 publications published. The most current publication "Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases." He accepts Medicare.
Publications
- Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell Lymphoma.
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory Lymphoma.
- Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin Lymphoma.
- Detection of classical Hodgkin Lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
- Chronic Myelomonocytic Leukemia with Nucleophosmin (NPM1) Mutation.
- Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma.
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
- A clinician's guide to double hit Lymphomas.
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Brentuximab vedotin for treatment of systemic T-cell Lymphoma.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-Cell non...
- Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma.
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
- Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone...
- Objective responses in relapsed T-cell Lymphomas with single agent brentuximab vedotin.
- Indolent peripheral T-cell Lymphoma involving the gastrointestinal tract.
- The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma.
- Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell Lymphoma? - Response to Lan...
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma.
- Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin Lymphoma.
- Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell Lymphoma.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed Lymphoma: a phase II clinical trial.
- Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed Lymphoma.
- Brentuximab vedotin in systemic T-cell Lymphoma.
- Limitations of the diagnostic criteria for minimally differentiated acute Myeloid leukemia (AML-MO)
- Philadelphia chromosome-positive acute lymphoblastic Leukemia in children.
- Successful bone marrow transplantation for adult T-cell Leukemia from a donor with oligoclonal proliferation of T-cells infected with human T-cell lymphotropic virus.
- Thalidomide in multiple Myeloma.
- A limitation of fluorescence in situ hybridization (FISH) assays targeting sex chromosomes for monitoring of early relapse after transplantation.
- Developing Novel Strategies to Target B-Cell Malignancies.
- A case of QT-interval prolongation precipitated by azithromycin.
- Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin Lymphoma.
- JAK2 mutation 1849G>T is rare in acute Leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic Leukemia.
- Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
- Silencing of bidirectional promoters by DNA methylation in tumorigenesis.
- Mutations and promoter methylation status of NPM1 in myeloproliferative Disorders.
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and Chronic myelomonocytic leukemia.
- Decitabine--bedside to bench.
- Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin Lymphoma.
- Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of Chronic myelogenous leukemia.
- Prognostic significance of serum B-lymphocyte stimulator in Hodgkin''s Lymphoma.
- Endothelial progenitor cells in non-Hodgkin''s Lymphoma.
- A parallel phase I/II clinical trial design for combination therapies.
- Elevated serum BLyS levels in patients with non-Hodgkin Lymphoma.
- Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cel...
- Treatment options in advanced Myelodysplastic syndrome, with emphasis on epigenetic therapy.
- Induction of hypomethylation and molecular response after decitabine therapy in patients with Chronic myelomonocytic leukemia.
- Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin Lymphoma.
- Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell Lymphoma, treated with CHOP- or RCHOP-based therapy.
- Current role of gemcitabine in the treatment of Hodgkin Lymphoma.
- Review: recent clinical trials in epigenetic therapy.
- Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell Lymphoma and suggests patients'' survival benefit from rituximab.
- Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and Lymphomas.
- R-CHOP therapy for MALT Lymphoma of the rectum.
- Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell Lymphoma.
- Analysis of prognostic factors in peripheral T-cell Lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
- Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem Cell transplantation after rituximab-cont...
- DNA methylation predicts survival and response to therapy in patients with Myelodysplastic syndromes.
- Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
- Epigenetic mechanisms in AML - a target for therapy.
- Does rituximab have a place in treating classic hodgkin Lymphoma?
- Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue Lymphoma.
- High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell Lymphoma.
- Clinical development of panobinostat in classical Hodgkin''s Lymphoma.
- Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell Lymphoma: analyses with competing risk regression model.
- Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin Lymphoma.
- Mocetinostat for relapsed classical Hodgkin's Lymphoma: an open-label, single-arm, phase 2 trial.
- Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin Lymphoma: associa...
- Clinical value of flow cytometric immunophenotypic analysis for minimal residual Disease detection in autologous stem-cell products of follicular and mantle cell lymph...
- Pneumocystis carinii pneumonia with an atypical granulomatous response in a patient with Chronic lymphocytic leukemia.
- Central nervous system involvement in pyothorax-associated Lymphoma: ring enhancement on CT scan.
- The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients.
Schools
Fac Med U Tokyo
St Lukes Roosevelt Hospital Center
MD Anderson Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
St Luke's-Roosevelt Hospital Center -
Graduate School of Medicine and Faculty of Medicine, The University of Tokyo
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1265742274 | |
| NPPES Provider LastName | OKI | |
| NPPES Provider FirstName | YASUHIRO | |
| NPPES Provider ZIPCode | 770304000 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 352.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 8.24 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265742274 |
| Last Name Of The Provider | OKI |
| First Name Of The Provider | YASUHIRO |
| View All |
Similar Doctors
|
|
Dr. Kelty R. Baker, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard P. Baltz, MD |
|
|
Dr. Mariana Chavez MacGregor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Giuseppe Fraschini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth K. Wu, MD |
|
|
Dr. Kristy L. Richards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Effrosyni Apostolidou, MD |
|
|
Dr. Sarvari V. Yellapragada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rammurti T. Kamble, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ken H. Young, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amin M. Alousi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amanda L. Olson, MD |
|
|
Dr. Michael J. Wagner, MD |
|
|
Alease L. Young |
|
Dr. Annie R. Su, MD
This Doctor is OpenDoctor Recommended.
|